NASDAQ:BMEA Biomea Fusion Q3 2026 Earnings Date & Estimates $0.56 -0.04 (-6.55%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more. Biomea Fusion is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026TimeAfter Market Closes Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Biomea Fusion in Q3 2026Biomea Fusion is expected to post earnings of -$0.2072 per share. In the same quarter a year earlier Biomea Fusion reported -$0.27 per share. Biomea Fusion last reported on August 5, 2026, posting -$0.12 per share and beating the -$0.2235 consensus estimate. Biomea Fusion has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.2072Prior-Year EPS-$0.27Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.12 (Beat by +$0.1035)EPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Biomea Fusion Q3 2026 Earnings FAQ When does Biomea Fusion report Q3 2026 earnings? Biomea Fusion (NASDAQ:BMEA) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Biomea Fusion's Q3 2026 earnings call? Biomea Fusion's Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 3:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Biomea Fusion? Analysts expect Biomea Fusion to post earnings of -$0.2072 per share for Q3 2026. Biomea Fusion Earnings HeadlinesBiomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026November 10 at 7:00 AM | globenewswire.comBiomea Fusion (BMEA) Projected to Post Quarterly Earnings on TuesdayNovember 2, 2026 | americanbankingnews.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 10 at 1:00 AM | Behind the Markets (Ad)What's going on with Biomea Fusion (BMEA) stock after hours?October 14, 2026 | msn.comBiomea Reports Phase 1 Weight-Loss Data For Oral GLP-1 Candidate BMF-650; Shares FallOctober 13, 2026 | rttnews.comBiomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss TranscriptOctober 13, 2026 | seekingalpha.comSee More Biomea Fusion Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email. Email Address About Biomea FusionBiomea Fusion (NASDAQ:BMEA) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for cancer and metabolic diseases. The company uses its proprietary FUSION System to discover and develop covalent medicines designed to engage disease-relevant protein targets. Biomea’s lead investigational product is BMF-219, an oral, selective covalent inhibitor of menin. The company has evaluated BMF-219 in clinical studies for certain hematologic malignancies and solid tumors, including acute leukemias and multiple myeloma, and has also investigated its potential in metabolic diseases such as type 2 diabetes. BMF-500 is another investigational program intended to target menin-related biology. Founded in 2017 and headquartered in Redwood City, California, Biomea Fusion conducts research and clinical development activities aimed at addressing diseases with significant unmet medical needs. The company is led by Thomas Butler, who serves as co-founder, chairman and chief executive officer. Its programs are investigational and have not been approved for commercial use by regulatory authorities.View Biomea Fusion ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
